Edition:
United States

Vitrolife AB (VITR.ST)

VITR.ST on Stockholm Stock Exchange

118.80SEK
11:14am EDT
Change (% chg)

-0.26kr (-0.22%)
Prev Close
119.06kr
Open
119.06kr
Day's High
119.88kr
Day's Low
116.96kr
Volume
35,266
Avg. Vol
122,728
52-wk High
143.86kr
52-wk Low
110.40kr

Latest Key Developments (Source: Significant Developments)

Vitrolife hikes dividend, Q4 EBITDA up yr/yr
Thursday, 8 Feb 2018 02:30am EST 

Feb 8 (Reuters) - Vitrolife Ab ::Q4 ‍SALES AMOUNTED TO SEK 271 (251) MILLION, CORRESPONDING TO AN INCREASE OF 8 PERCENT IN SEK​.Q4 ‍SALES GROWTH WAS 11 PERCENT IN LOCAL CURRENCY AND CONSISTED IN ITS ENTIRETY OF ORGANIC GROWTH.​.Q4 ‍OPERATING INCOME BEFORE DEPRECIATION AND AMORTISATION (EBITDA) AMOUNTED TO SEK 103 (96) MILLION, CORRESPONDING TO A MARGIN OF 38 (38) PERCENT​.SAYS ‍BOARD PROPOSES A DIVIDEND OF SEK 3.70 (2.60) PER SHARE​.  Full Article

Vitrolife buys licensing rights for embryo transfer technology
Thursday, 11 Jan 2018 02:33am EST 

Jan 11 (Reuters) - Vitrolife AB ::VITROLIFE ACQUIRES LICENSING RIGHTS TO TECHNOLOGY FOR EMBRYO TRANSFER.SAYS ‍INTENDS TO COMMERCIALISE TECHNOLOGY BY MARKETING A UNIQUE EMBRYO TRANSFER CATHETER​.SAYS ‍INITIAL PURCHASE PRICE AMOUNTED TO USD 5 MILLION​.SAYS ‍ACQUISITION IS EXPECTED TO IMPACT EBITDA PER SHARE MARGINALLY NEGATIVELY DURING 2018-2020 AND POSITIVELY AS FROM 2021​.  Full Article

Vitrolife Q3 core profit rises, like-for-like sales grow 20 pct​
Thursday, 2 Nov 2017 03:30am EDT 

Nov 2 (Reuters) - Vitrolife AB :Q3 ‍sales amounted to SEK 246 (210) million, corresponding to an increase of 17 percent in SEK​.Q3 ‍sales growth was 20 percent in local currency and consisted in its entirety of organic growth​.Q3 ‍operating income before depreciation and amortisation (EBITDA) amounted to SEK 98 (71) million, corresponding to a margin of 40 (34) percent​.Says looking ahead, the market outlook is essentially unchanged.  Full Article

Vitrolife Q2 EBITDA rises to SEK 112 mln
Friday, 14 Jul 2017 02:30am EDT 

July 14 (Reuters) - Vitrolife AB :Q2 sales amounted to SEK 285 (208) million.Q2 operating income before depreciation and amortisation (EBITDA) amounted to SEK 112 (74) million.Says anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future.  Full Article

Vitrolife Q1 EBITDA rises 53 pct yr/yr
Tuesday, 25 Apr 2017 02:30am EDT 

April 25 (Reuters) - Vitrolife AB :Q1 sales amounted to SEK 244 (187) million.Q1 operating income before depreciation and amortisation (EBITDA) amounted to SEK 95 (62) million.Q1 net sales growth was 27 percent in local currency.Looking ahead, the market outlook is essentially unchanged and Vitrolife therefore anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future.  Full Article

Vitrolife Q4 core profit rose to SEK 96 mln
Thursday, 9 Feb 2017 02:30am EST 

Vitrolife Ab : Q4 sales amounted to SEK 251 (199) million, corresponding to an increase of 26 percent in SEK. Net sales growth was 21 percent in local currency. . Q4 operating income before depreciation and amortisation (ebitda) amounted to SEK 96 (81) million . Q4 board proposes a dividend of SEK 2.60 (2.40) per share. .Says looking ahead, the market outlook is essentially unchanged and Vitrolife therefore anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future..  Full Article

Vitrolife Q3 EBITDA profit narrows to SEK 71 mln
Thursday, 3 Nov 2016 03:30am EDT 

Vitrolife AB : Q3 sales amounted to SEK 210 (177) million .Q3 operating income before depreciation and amortisation (EBITDA) amounted to SEK 71 (82) million.  Full Article

BRIEF-Vitrolife Q1 operating profit rises

* VITROLIFE AB Q1 OPERATING INCOME BEFORE DEPRECIATION AND AMORTISATION (EBITDA) AMOUNTED TO SEK 106 (95) MILLION Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)